ZHAOKE OPHTH-B(06622): The Australian Therapeutic Goods Administration has accepted the registration application for Atropine Sulfate Eye Drops (0.02% dosage) for treatment.

Zhaoke OPHTH-B(06622) announced that on June 2, 2026, the Australian Therapeutic Goods Administration accepted the registration application from the evaluation company for its atropine sulfate eye drops (0.02% dosage, product code: NVK002) used to slow down the progression of myopia in children. The Therapeutic Goods Administration has officially notified the company that the application has passed the initial review and will undergo evaluation. The application is based on supportive results from the company's Phase III clinical trials. The atropine sulfate eye drops (NVK002) are a type of eye drops used to slow down the progression of myopia in children and adolescents. The atropine sulfate eye drops (NVK002) is a patented formula that effectively addresses the instability of low concentration atropine. This technology is protected by intellectual property rights globally. The eye drops do not contain preservatives and have an estimated shelf life of 24 months.